Voyageur Pharmaceuticals Advances Vertical Integration Strategy for Barium and Iodine Contrast Media

Voyageur Pharmaceuticals Ltd. is advancing a comprehensive strategy to address supply chain vulnerabilities in the diagnostic imaging sector, where demand is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033 according to Research Contrast. With barite classified as a critical mineral by the U.S. Geological Survey, the company aims to create a secure, vertically integrated supply chain for both barium and iodine active pharmaceutical ingredients to manufacture contrast media drugs. This approach encompasses the entire value chain from mineral discovery to finished product manufacturing to ensure supply security and competitive production costs.

The company is currently focused on completing two bankable feasibility studies that underpin this vertically integrated strategy: the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. These projects represent foundational steps toward establishing a resilient, North American–based supply chain capable of supporting growing global demand for diagnostic imaging pharmaceuticals. Voyageur is actively advancing the Frances Creek barium contrast project, now in the BFS phase, which hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical grade barium sulfate. Recent testing confirms the FC barite purity exceeds Pharmaceutical Grade (97.5%), with an average grade 98.8% BaSO4, as detailed in the news release dated March 4, 2026.

Voyageur has completed product development initiatives for five Health Canada approved barium products with Alberta Veterinary Laboratories, a GMP pharmaceutical manufacturer, to produce barium contrast products using imported barium sulfate. The company has generated approximately C$32,000 in initial contrast product sales, establishing commercial validation. Sales and pricing data across Canadian and international markets contribute to demonstrating the manufacturing advantages and margin potential of Voyageur’s vertically integrated FC barium project. The company completed a preliminary economic assessment that valued the FC barium contrast project with a NPV of $344M, as reported in the news release dated January 11, 2022.

Regulatory pathways for barium and iodine contrast media are expected to follow an 18 to 24-month FDA review and approval process, potentially enabling U.S. barium market entry as soon as mid 2027 to late 2027. FDA approval, recognized globally, will also allow for registration of products in the European Union and other international markets, expanding Voyageur’s global growth opportunities. The company has completed the first drafts of all barium FDA submission documents and formally commenced the approval process in February 2026 via the 505(b)(2) regulatory pathway. Building on this momentum, Voyageur plans to advance a generic iodine FDA license in the second half of 2026, further strengthening its pharmaceutical portfolio.

Voyageur is independently advancing a prefeasibility study for iodine contrast media drug production, integrating the Mueller iodine extraction process with the Streamline iodine drug manufacturing platform. The project leverages iodine-rich brine sourced from oil and gas operations and water disposal companies in the United States, targeting 35 million doses per year of iodine contrast drug production. These two processes combined are expected to lower costs to manufacture iodine drugs significantly. Voyageur’s iodine strategy is also anchored by the Bayer Iodine production project, which focuses on completing a BFS. This collaboration, which began with the signing of an LOI with Bayer on December 20, 2024, represents an important early step in Voyageur's mission to become the first domestic producer of iodine contrast in the United States.

The company is engaging with a global engineering company to complete the final two BFS for the Voyageur radiology drug manufacturing project and the Bayer Iodine project. Upon completion of the two BFS, Voyageur will have finalized the economics and plant design to vertically produce iodine and barium contrast media drugs, becoming the only vertically integrated radiology drug company in the marketplace. Voyageur is actively reviewing its financial options to fund future capital expenditures, targeting funding based on the finalized feasibility studies and plant construction for the Bayer project and for Voyageur’s barium and iodine contrast pharmaceutical manufacturing, targeting construction to commence in 2027. Management believes these efforts will position Voyageur as the only vertically integrated manufacturer of barium and iodine contrast media globally, providing affordable and secure supplies for healthcare authorities worldwide.